The federal contract award SPE2DB24D8001 to Dakota Drug, Inc., a self-certified small disadvantaged business, provides for the delivery of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense through the Defense Logistics Agency (DLA) Troop Support Medical program. This single-award Indefinite Delivery Contract (IDC), valued at $999,999,999.00, allows Dakota Drug, Inc. to supply a comprehensive range of critical medical items, including treatments for conditions such as diabetes, asthma, COPD, hypertension, and autoimmune disorders. The contract, which does not have a set-aside designation, is part of the DLA's ECAT Generation V Program and will run through December 31, 2025, solidifying Dakota Drug, Inc.'s role as a key supplier for the DLA's military medical supply operations.
Additionally, the agency awarded Dakota Drug, Inc. a separate delivery order contract, SPE2DB24FKZCV, for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS, with a ceiling value of $5,253.48 and a completion date of September 27, 2024. This contract is also structured as a firm fixed-price delivery order.
Generated 12/26/24, 9:29 AM